EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring

Joaquim Faria Monteiro iD, Alexandrina Fernandes, Diogo Gavina Tato iD, Elias Moreira, Ricardo Ribeiro iD, Henrique Reguengo iD, Jorge Gonçalves iD, Paula Fresco iD

Cancers · 08.10.2025 · 17 (19) · 3262

DOI: 10.3390/cancers17193262 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.10.2025. Verfasst von Joaquim Faria Monteiro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Farmacologia, Departamento de Ciências do Medicamento, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-PD-1 therapies have transformed cancer treatment by restoring antitumor T cell activity. Despite their broad clinical use, variability in treatment response and immune-related adverse events underscore the need for therapeutic optimization. This article provides an integrative overview of the pharmacokinetics (PKs) of anti-PD-1 antibodies—such as nivolumab, pembrolizumab, and cemiplimab—and examines pharmacokinetic–pharmacodynamic (PK-PD) relationships, highlighting the impact of clearance variability on drug exposure, efficacy, and safety. Baseline clearance and its reduction during therapy, together with interindividual variability, emerge as important dynamic biomarkers with potential applicability across different cancer types for guiding individualized dosing strategies. The review also discusses established biomarkers for anti-PD-1 therapies, including tumor PD-L1 expression and immune cell signatures, and their relevance for patient stratification. The evidence supports a shift from traditional weight-based dosing toward adaptive dosing and therapeutic drug monitoring (TDM), especially in long-term responders and cost-containment contexts. Notably, the inclusion of clearance-based biomarkers—such as baseline clearance and its reduction—into therapeutic models represents a key step toward individualized, dynamic immunotherapy. In conclusion, optimizing anti-PD-1 therapy through PK-PD insights and biomarker integration holds promise for improving outcomes and reducing toxicity. Future research should focus on validating PK-based approaches and developing robust algorithms (machine learning models incorporating clearance, tumor burden, and other validated biomarkers) for tailored cancer treatment.

Schlagwörter

Stichwörter der Autor:innen

anti-PD-1 drugsbiomarkerscancerclearanceimmune checkpoint inhibitorspharmacokineticstherapeutic drug monitoring

Autor:innen und Institutionen

  • Laboratório de Farmacologia, Departamento de Ciências do Medicamento, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal.
  • UCIBIO, Unidade de Ciências Biomoleculares Aplicadas, Laboratório Associado i4HB, Instituto para a Saúde e Bioeconomia, Faculdade de Farmácia, Universidade do Porto, 4050-313 Porto, Portugal.
  • Serviços Farmacêuticos, Unidade Local de Saúde São João, 4200-319 Porto, Portugal.
  • Clinical Chemistry, Clinic of Genetics and Pathology, Centro Hospitalar de Santo António, 4099-001 Porto, Portugal.
  • Tumour and Microenvironment Interactions Group, i3S Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
  • Unit for Multidisciplinary Research in Biomedicine (UMIB), Institute of Biomedical Sciences Abel Salazar (ICBAS), Universidade do Porto, 4050-313 Porto, Portugal.

ORCID-Profile: Joaquim Faria Monteiro, Diogo Gavina Tato, Ricardo Ribeiro, Henrique Reguengo, Jorge Gonçalves, Paula Fresco

Zitieren

APA

Monteiro, J. F., Fernandes, A., Tato, D. G., Moreira, E., Ribeiro, R., Reguengo, H., Gonçalves, J., & Fresco, P. (2025). Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring. Cancers, 17(19), 3262. https://doi.org/10.3390/cancers17193262

Vancouver

Monteiro JF, Fernandes A, Tato DG, Moreira E, Ribeiro R, Reguengo H, et al. Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring. Cancers. 2025;17(19):3262. doi:10.3390/cancers17193262

BibTeX
@article{Monteiro2025,
  author = {Monteiro, Joaquim Faria and Fernandes, Alexandrina and Tato, Diogo Gavina and Moreira, Elias and Ribeiro, Ricardo and Reguengo, Henrique and Gonçalves, Jorge and Fresco, Paula},
  title = {Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {19},
  pages = {3262},
  doi = {10.3390/cancers17193262}
}
Kostenlos starten →